The Study of a Selective Serotonin Partial Agonist and Reuptake Inhibitors, HEC113995PA•H2O,in Healthy Subjects

Healthy Clinical Trial

Official title:

Safety, Tolerability, and Pharmacokinetics Phase ⅠStudy of a Selective Serotonin Partial Agonist and Reuptake Inhibitors, HEC113995PA•H2O, Following Single Ascending Doses，Single-center, Randomized, Double-blind in Healthy Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03943251
• Other study ID #: HEC113995PA•H2O-P-01/CRC-C19
• Status: Completed
• Phase: Phase 1
• Start date: July 4, 2019
• Est. completion date: December 11, 2019

Study information

• Verified date: May 2021
• Source: Sunshine Lake Pharma Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a safety, tolerability, and pharmacokinetics phase Ⅰstudy of a selective Serotonin partial agonist and reuptake inhibitors, HEC113995PA•H2O,in healthy subjects.This study is the healthy adult subjects single ascending-dose research.

Description:

There have set up seven dose group(2.5、5、10、20、40、60、80mg）.The first group(2.5mg)contains 8 health subjects(6 health subjects take experimental drugs,2 health subjects take the placebo). Other groups contains 10 health subjects(8 health subjects take experimental drugs,2 health subjects take the placebo).Within 30min before taking the medicine and after 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 8h, 10h, 24h, 36h, 48h,72h to take blood samples for pharmacokinetics(PK) detection.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 69
• Est. completion date: December 11, 2019
• Est. primary completion date: December 11, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Willing to participate in the study, able to understand and sign the informed consent, and able to complete the the study in accordance with the requirements of the study.
• Female subjects who are not pregnant or lactating and male subjects whose female partners are fertile shall voluntarily take effective contraceptive measures from the date of signing the informed consent form to 3 months after the medication.
• When signing the informed consent, 18 years old =the age=45 years old, gender is not limited.
• Male body weight =50kg, female body weight =45kg, and body mass index (BMI) in the range of 18-28 kg/m2 (including the critical value).
• No clinical significance of vital signs, physical examination, laboratory examination, chest X-ray (posterior and anterior) and electrocardiogram results.

Exclusion Criteria:

• The serum creatinine, ALT and AST levels =1.5 times of the normal upper limit in the screening period.
• The HbsAg, anti-HCV, HIV-antibody or syphilis antibody is positive in screening.
• Patients with clinical significance of the following diseases, including but not limited to gastrointestinal, kidney, liver, nerve, blood, endocrine, tumor, lung, immune, mental or cardiovascular diseases, epilepsy, bipolar disorder/mania, high intraocular pressure or acute angle-closure glaucoma disease history.
• Those who are known to have allergy history or allergy constitution to the test preparation and any of its components or related preparations.
• Any prescription or over-the-counter medication taken within 14 days prior to starting the study drug, or any drug that inhibits or induces the liver to metabolize the drug within 28 days [e.g., inducer - the barbiturates, rifampicin, carbamazepine, phenytoin, omeprazole, griseofulvin, ammonia methyl propyl ester, etc.; inhibitors - large ring lactone class antibiotic (such as erythromycin, clarithromycin, etc.), azole antifungal drugs (such as ketone health zun, itraconazole, etc.), fluoroquinolone (e.g., ciprofloxacin, sand magnitude), calcium channel blockers (such as verapamil, diltiazem, etc.), H1 receptor antagonist (e.g., astemizole, etc.), H2 receptor antagonist (e.g., cimetidine, etc.), SSRI antidepressants (such as fluoxetine, fluvoxamine, etc.), benzodiazepines a tranquilizer, clopidogrel, gemfibrozil, deferasirox, teriflunomide, telithromycin, trimethoprim, HMG-CoA reductase inhibitors (such as lovastatin, simvastatin, etc.), nitroimidazoles, etc.
• Those who ingested food or drink containing caffeine, xanthine, alcohol or grapefruit within 48 hours before taking the study drug.
• The urine drug abuse screening(morphine, tetrahydrocannabinolate, methamphetamine, dimethylene dioxyamphetamine, ketamine, and cocaine) is positive.
• Intemperant or regular drinkers within 3 months prior to the study, i.e., those who consumed more than 21 units of alcohol per week (1 unit =360mL beer or 45mL spirit with 40% alcohol or 150mL wine), or those who were positive on the alcohol breath test.
• A heavy smoker or smokers who smoke more than 10 cigarettes per day within 3 months prior to administration or who fail to comply with the no smoking regulation during the study.
• Those who had a blood donation or blood loss of >400mL within one month before taking the study drug.
• Those who plan to receive an organ transplant or have had one.
• Those who have participated in clinical trials of other drugs within 3 months before randomization.
• Subjects considered by the investigator to have other factors unsuitable for participation in this study.

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• HEC113995PA•H2O tablet
2.5-?5-?10-?20-?40-?60-?80mg HEC113995PA•H2O tablet in day1.
• Placebo tablet
2.5-?5-?10-?20-?40-?60-?80mg Placebo tablet in day1.

Locations

Country	Name	City	State
China	The Shanghai xuhui district central hospital	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Sunshine Lake Pharma Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Mean Residence Time(MRT)	Mean Residence Time(MRT) of HEC113995PA•H2O in single ascending-dose	Prior to dosing(0.5h)and 0.5h,1h,1.5h,2h,2.5h,3h,4h,5h,6h,8h,10h,12h,24h,36h,48h,72h after dosing
Other	Terminal elimination half-life(T1/2)	Terminal elimination half-life(T1/2) of HEC113995PA•H2O in single ascending-dose	Prior to dosing(0.5h)and 0.5h,1h,1.5h,2h,2.5h,3h,4h,5h,6h,8h,10h,12h,24h,36h,48h,72h after dosing
Primary	Adverse events of the single ascending-dose	To assess the safe and tolerability of the single ascending-dose	From the baseline to day4
Secondary	Maximum Plasma Concentration(Cmax)	Maximum Plasma Concentration(Cmax)of HEC113995PA•H2O in single ascending-dose	Prior to dosing(0.5h)and 0.5h,1h,1.5h,2h,2.5h,3h,4h,5h,6h,8h,10h,12h,24h,36h,48h,72h after dosing
Secondary	Area Under the Curve(AUC)	Area Under the Curve(AUC) of HEC113995PA•H2O in single ascending-dose	Prior to dosing(0.5h)and 0.5h,1h,1.5h,2h,2.5h,3h,4h,5h,6h,8h,10h,12h,24h,36h,48h,72h after dosing
Secondary	Maximum Peak Time(Tmax)	Maximum Peak Time(Tmax) of HEC113995PA•H2O in single ascending-dose	Prior to dosing(0.5h)and 0.5h,1h,1.5h,2h,2.5h,3h,4h,5h,6h,8h,10h,12h,24h,36h,48h,72h after dosing